{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:16:34Z","timestamp":1774736194884,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sohag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the efficacy of baricitinib compared to TNF-\u03b1 Inhibitors and conventional DMARDs (cDMARDs) in patients with RA. Our study included 334 RA patients classified into 3 groups: the first receiving baricitinib, the second receiving TNF-\u03b1 Inhibitors, and the third receiving cDMARDs. Patients were evaluated at baseline, week 12, and week 24 using TJC, SJC, VAS, DAS28, CDAI, and HAQ-DI. Larsen score was measured at baseline and 24\u00a0weeks. The response to therapy was assessed at weeks 12 and 24 using ACR 20, ACR 50, and ACR 70 response criteria. Emerging treatment side effects were monitored. Patients receiving baricitinib showed significant improvement regarding all outcome measures at weeks 12 and 24. In addition, baricitinib was comparable to TNF Inhibitors in all outcome measures except the ACR 70 at week 12, which was higher in the baricitinib group. Furthermore, baricitinib group showed significantly better outcome measures and response to therapy in comparison to cDMARDs group. The most common side effects in the baricitinib group were infection, GIT, and CVS complications. The most common side effects in the TNF inhibitors group were infection and skin complications. The cDMARDs had the least side effects, mostly GIT complications. Baricitinib is an effective drug for treating RA refractory to cDMARDs, improving disease activity measures and functional status and reducing the progression of structural joint damage. It has a comparable efficacy and safety profile to TNF Inhibitors. Multicenter studies are recommended to support our results.\n<jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Baricitinib is an effective therapeutic choice for rheumatoid arthritis refractory to cDMARDs.<\/jats:italic>\u2022 <jats:italic>Patients treated with baricitinib showed improvement in all outcome measures and functional status.<\/jats:italic>\u2022 <jats:italic>Bricitinib delayed the progression of radiographic joint damage more effectively than cDMARDs.<\/jats:italic>\u2022 <jats:italic>The efficacy and safety of baricitinib for treating rheumatoid arthritis is comparable to that of TNF inhibitors.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s10067-024-07194-x","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T12:02:15Z","timestamp":1730376135000},"page":"3657-3668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-\u03b1 inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients"],"prefix":"10.1007","volume":"43","author":[{"given":"Esraa M.","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-1750","authenticated-orcid":false,"given":"Sahar A.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"7194_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pop.2018.02.010","volume":"45","author":"EA Littlejohn","year":"2018","unstructured":"Littlejohn EA, Monrad SU (2018) Early diagnosis and treatment of rheumatoid arthritis. Prim Care 45:237\u2013255. https:\/\/doi.org\/10.1016\/j.pop.2018.02.010","journal-title":"Prim Care"},{"key":"7194_CR2","unstructured":"Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R (2010) Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur). 5: 286\u201391.\u00a0https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3152850\/"},{"key":"7194_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-018-8714-z","volume":"58","author":"F Carbone","year":"2020","unstructured":"Carbone F, Bonaventura A, Liberale L, Paolino S, Torre F, Dallegri F, Cutolo M et al (2020) Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents. Clin Rev Allergy Immunol 58:1\u201314. https:\/\/doi.org\/10.1007\/s12016-018-8714-z","journal-title":"Clin Rev Allergy Immunol"},{"key":"7194_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.mcna.2020.10.006","volume":"105","author":"JJ Cush","year":"2021","unstructured":"Cush JJ (2021) Rheumatoid Arthritis: Early Diagnosis and Treatment. Med Clin North Am 105:355\u2013365. https:\/\/doi.org\/10.1016\/j.mcna.2020.10.006","journal-title":"Med Clin North Am"},{"key":"7194_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","volume":"71","author":"BR England","year":"2019","unstructured":"England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, Michaud K et al (2019) 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res 71:1540\u20131555. https:\/\/doi.org\/10.1002\/acr.24042","journal-title":"Arthritis Care Res"},{"key":"7194_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Akl EA et al (2021) 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol (Hoboken, N.J.) 73:1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol (Hoboken, N.J.)"},{"key":"7194_CR7","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE (2017) Novel treatment strategies in rheumatoid arthritis. Lancet (London, England) 389:2338\u20132348. https:\/\/doi.org\/10.1016\/S0140-6736(17)31491-5","journal-title":"Lancet (London, England)"},{"key":"7194_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA 320:1360\u20131372. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"7194_CR9","doi-asserted-by":"crossref","unstructured":"Shah P, Siddique A, Thakkar A, Gharat S, Godad A, Kale P, Doshi G (2022) An update on novel therapeutic intervention in Rheumatoid arthritis. Int Immunopharmacol 109:108794.\u00a0https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/2705192","DOI":"10.1016\/j.intimp.2022.108794"},{"key":"7194_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2298\/vsp0601021p","volume":"63","author":"L Petrovi\u0107-Rackov","year":"2006","unstructured":"Petrovi\u0107-Rackov L (2006) Evaluation of the degree of clinical rheumatoid arthritis activity based on the concentrations of cytokines TNF-alpha, IL-12, IL-15, and IL-18 in serum and synovial fluid. Vojnosanit Pregl 63:21\u201326. https:\/\/doi.org\/10.2298\/vsp0601021p","journal-title":"Vojnosanit Pregl"},{"key":"7194_CR11","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1186\/ar3188","volume":"12","author":"S Visvanathan","year":"2010","unstructured":"Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Wagner C et al (2010) Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 12:R211. https:\/\/doi.org\/10.1186\/ar3188","journal-title":"Arthritis Res Ther"},{"key":"7194_CR12","doi-asserted-by":"publisher","unstructured":"Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, et al Etanercept in Early Rheumatoid Arthritis Trial G, (2010) Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheumatism 62: 674-682. https:\/\/doi.org\/10.1002\/art.27268.","DOI":"10.1002\/art.27268"},{"key":"7194_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R (2020) JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data. J Inflamm Res 13:519\u2013531. https:\/\/doi.org\/10.2147\/JIR.S219586","journal-title":"J Inflamm Res"},{"key":"7194_CR14","doi-asserted-by":"crossref","unstructured":"Hu L, Liu R, Zhang L (2022) Advance in bone destruction participated by JAK\/STAT in rheumatoid arthritis and therapeutic effect of JAK\/STAT inhibitors. Int Immunopharmacol 111:109095. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1567576922005793","DOI":"10.1016\/j.intimp.2022.109095"},{"key":"7194_CR15","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","volume":"61","author":"A Barbulescu","year":"2022","unstructured":"Barbulescu A, Askling J, Chatzidionysiou K, Forsblad-d\u2019Elia H, Kastbom A, Lindstr\u00f6m U, Frisell T et al (2022) Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford) 61:3952\u20133962. https:\/\/doi.org\/10.1093\/rheumatology\/keac068","journal-title":"Rheumatology (Oxford)"},{"key":"7194_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Cohen MD et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheumatism. 62:2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheumatism."},{"key":"7194_CR17","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, Elkayam O et al (2022) Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019collaboration. Ann Rheum Dis 81:1358\u20131366","journal-title":"Ann Rheum Dis"},{"key":"7194_CR18","doi-asserted-by":"publisher","first-page":"e088","DOI":"10.5435\/JAAOSGlobal-D-17-00088","volume":"2","author":"DA Delgado","year":"2018","unstructured":"Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD (2018) Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. JAAOS Global Research & Reviews 2:e088. https:\/\/doi.org\/10.5435\/JAAOSGlobal-D-17-00088","journal-title":"JAAOS Global Research & Reviews"},{"key":"7194_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5114\/reum.2015.53999","volume":"53","author":"TA Barczy\u0144ska","year":"2015","unstructured":"Barczy\u0144ska TA, Dura M, Blumfield E, W\u0119gierska M, \u017buchowski P, Wili\u0144ska-Jankowska A, Jeka S (2015) DAS28 score vs. ultrasound examination for assessment of rheumatoid arthritis disease activity: comparison and discussion of pros and cons. Reumatologia\/Rheumatology 53:213\u2013218. https:\/\/doi.org\/10.5114\/reum.2015.53999","journal-title":"Reumatologia\/Rheumatology"},{"key":"7194_CR20","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1111\/1756-185X.13110","volume":"21","author":"P Dhaon","year":"2018","unstructured":"Dhaon P, Das SK, Srivastava R, Dhakad U (2018) Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. Int J Rheum Dis 21:1933\u20131939. https:\/\/doi.org\/10.1111\/1756-185X.13110","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 11","key":"7194_CR21","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/acr.20620","volume":"63","author":"L Maska","year":"2011","unstructured":"Maska L, Anderson J, Michaud K (2011) Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res 63(Suppl 11):S4-13. https:\/\/doi.org\/10.1002\/acr.20620","journal-title":"Arthritis Care Res"},{"key":"7194_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735. https:\/\/doi.org\/10.1002\/art.1780380602","journal-title":"Arthritis Rheum"},{"key":"7194_CR23","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","volume":"41","author":"DT Felson","year":"1998","unstructured":"Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP (1998) Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41:1564\u20131570. https:\/\/doi.org\/10.1002\/1529-0131(199809)41:9%3c1564::AID-ART6%3e3.0.CO;2-M","journal-title":"Arthritis Rheum"},{"key":"7194_CR24","unstructured":"Rau R, Herborn G (1995) A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis. J Rheumatol 22:1976\u20131982.\u00a0https:\/\/www.researchgate.net\/publication\/14216212"},{"key":"7194_CR25","doi-asserted-by":"publisher","first-page":"111487","DOI":"10.1016\/j.intimp.2024.111487","volume":"128","author":"X Zhong","year":"2024","unstructured":"Zhong X, Feng W, Liu L, Liu Q, Xu Q, Liu M, Lin C et al (2024) Periplogenin inhibits pathologic synovial proliferation and infiltration in rheumatoid arthritis by regulating the JAK2\/3-STAT3 pathway. Int Immunopharmacol 128:111487. https:\/\/doi.org\/10.1016\/j.intimp.2024.111487","journal-title":"Int Immunopharmacol"},{"key":"7194_CR26","doi-asserted-by":"publisher","unstructured":"Radu AF, Bungau SG (2021) Management of Rheumatoid Arthritis: An Overview. Cells. 10. https:\/\/doi.org\/10.3390\/cells10112857.","DOI":"10.3390\/cells10112857"},{"key":"7194_CR27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.autrev.2014.08.026","volume":"13","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Meroni PL (2014) Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an \u201canchor\u201d drug? Autoimmun Rev 13:1102\u20131108. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.026","journal-title":"Autoimmun Rev"},{"key":"7194_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/BOR.0000000000000153","volume":"27","author":"MK Sethi","year":"2015","unstructured":"Sethi MK, O\u2019Dell JR (2015) Combination conventional DMARDs compared to biologicals: what is the evidence? Curr Opin Rheumatol 27:183\u2013188. https:\/\/doi.org\/10.1097\/BOR.0000000000000153","journal-title":"Curr Opin Rheumatol"},{"key":"7194_CR29","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet (London, England) 370:1861\u20131874. https:\/\/doi.org\/10.1016\/S0140-6736(07)60784-3","journal-title":"Lancet (London, England)"},{"key":"7194_CR30","doi-asserted-by":"publisher","first-page":"1387585","DOI":"10.3389\/fphar.2024.1387585","volume":"15","author":"W Cai","year":"2024","unstructured":"Cai W, Tong R, Sun Y, Yao Y, Zhang J (2024) Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol 15:1387585. https:\/\/doi.org\/10.3389\/fphar.2024.1387585","journal-title":"Front Pharmacol"},{"key":"7194_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Smolen JS et al (2016) Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med 374:1243\u20131252. https:\/\/doi.org\/10.1056\/NEJMoa1507247","journal-title":"N Engl J Med"},{"key":"7194_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s42358-023-00331-1","volume":"63","author":"X Liao","year":"2023","unstructured":"Liao X, Huo W, Zeng W, Qin F, Dong F, Wei W, Lei L (2023) Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial. Advances in Rheumatology 63:50. https:\/\/doi.org\/10.1186\/s42358-023-00331-1","journal-title":"Advances in Rheumatology"},{"key":"7194_CR33","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.150613","volume":"43","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W (2016) Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. J Rheumatol 43:504\u2013511. https:\/\/doi.org\/10.3899\/jrheum.150613","journal-title":"J Rheumatol"},{"key":"7194_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2015-eular.6539","volume":"74","author":"M Dougados","year":"2015","unstructured":"Dougados M, Dvd H, Chen Y-C, Greenwald M, Drescher E, Liu J, Emery P et al (2015) LB0001 Baricitinib, an Oral Janus Kinase (JAK)1\/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. Ann Rheum Dis 74:79\u201379. https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.6539","journal-title":"Ann Rheum Dis"},{"key":"7194_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/annrheumdis-2015-eular.1427","volume":"74","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Smolen JS et al (2015) OP0029 Baricitinib, An Oral Janus Kinase (JAK)1\/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. Ann Rheum Dis 74:75\u201376. https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.1427","journal-title":"Ann Rheum Dis"},{"key":"7194_CR36","doi-asserted-by":"publisher","first-page":"e000410","DOI":"10.1136\/rmdopen-2016-000410","volume":"3","author":"P Emery","year":"2017","unstructured":"Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, Dougados M et al (2017) Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open 3:e000410. https:\/\/doi.org\/10.1136\/rmdopen-2016-000410","journal-title":"RMD Open"},{"key":"7194_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz P-Y, Genovese MC et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74:333\u2013340. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206478","journal-title":"Ann Rheum Dis"},{"key":"7194_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, Tanaka Y et al (2017) Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 376:652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"key":"7194_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.medcli.2018.10.020","volume":"152","author":"JM Serra L\u00f3pez-Matencio","year":"2019","unstructured":"Serra L\u00f3pez-Matencio JM, Morell Baladr\u00f3n A, Casta\u00f1eda S (2019) JAK-STAT inhibitors for the treatment of immunomediated diseases. Med Clin (Barc) 152:353\u2013360. https:\/\/doi.org\/10.1016\/j.medcli.2018.10.020","journal-title":"Med Clin (Barc)"},{"key":"7194_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0378-1119(02)00398-0","volume":"285","author":"T Kisseleva","year":"2002","unstructured":"Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK\/STAT pathway, recent advances and future challenges. Gene 285:1\u201324. https:\/\/doi.org\/10.1016\/s0378-1119(02)00398-0","journal-title":"Gene"},{"key":"7194_CR41","doi-asserted-by":"publisher","first-page":"e004291","DOI":"10.1136\/rmdopen-2024-004291","volume":"10","author":"CJ van de Laar","year":"2024","unstructured":"van de Laar CJ, Voshaar MAO, Ten Klooster P, Tedjo DI, Bos R, Jansen T, Kroot E-J et al (2024) PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. RMD Open 10:e004291","journal-title":"RMD Open"},{"key":"7194_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Takeuchi T et al (2017) Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. Arthritis Rheumatol 69:506\u2013517. https:\/\/doi.org\/10.1002\/art.39953","journal-title":"Arthritis Rheumatol"},{"key":"7194_CR43","doi-asserted-by":"publisher","first-page":"e000898","DOI":"10.1136\/rmdopen-2019-000898","volume":"5","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Schiff M, Tanaka Y, Xie L, Meszaros G, Ishii T, Emery P et al (2019) Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open 5:e000898. https:\/\/doi.org\/10.1136\/rmdopen-2019-000898","journal-title":"RMD Open"},{"key":"7194_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13075-020-02379-6","volume":"23","author":"P Emery","year":"2021","unstructured":"Emery P, Durez P, Hueber AJ, de la Torre I, Larsson E, Holzk\u00e4mper T, Tanaka Y (2021) Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review. Arthritis Res Ther 23:3. https:\/\/doi.org\/10.1186\/s13075-020-02379-6","journal-title":"Arthritis Res Ther"},{"key":"7194_CR45","doi-asserted-by":"publisher","first-page":"e0181126","DOI":"10.1371\/journal.pone.0181126","volume":"12","author":"K Murakami","year":"2017","unstructured":"Murakami K, Kobayashi Y, Uehara S, Suzuki T, Koide M, Yamashita T, Nakamura Y et al (2017) A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE 12:e0181126. https:\/\/doi.org\/10.1371\/journal.pone.0181126","journal-title":"PLoS ONE"},{"key":"7194_CR46","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:234\u2013243. https:\/\/doi.org\/10.1038\/nrrheum.2017.23","journal-title":"Nat Rev Rheumatol"},{"key":"7194_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40259-018-0304-3","volume":"32","author":"F Huang","year":"2018","unstructured":"Huang F, Luo Z-C (2018) Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BioDrugs: Clinical Immunotherapeutics. Biopharmaceuticals and Gene Therapy 32:415\u2013423. https:\/\/doi.org\/10.1007\/s40259-018-0304-3","journal-title":"Biopharmaceuticals and Gene Therapy"},{"key":"7194_CR48","doi-asserted-by":"publisher","first-page":"814429","DOI":"10.3389\/fimmu.2022.814429","volume":"13","author":"B He","year":"2022","unstructured":"He B, Li Y, Luo W-w, Cheng X, Xiang H-r, Zhang Q-z, Peng W-x et al (2022) The Risk of Adverse Effects of TNF-\u03b1 Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis. Front Immunol 13:814429. https:\/\/doi.org\/10.3389\/fimmu.2022.814429","journal-title":"Front Immunol"},{"key":"7194_CR49","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/acr.22096","volume":"65","author":"MV Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez MV, Sanmart\u00ed R, Ca\u00f1ete JD, Descalzo MA, Alsina M, Carmona L, Gomez-Reino JJ (2013) Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken) 65:2024\u20132031. https:\/\/doi.org\/10.1002\/acr.22096","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7194_CR50","doi-asserted-by":"publisher","first-page":"566160","DOI":"10.3389\/fmed.2020.566160","volume":"7","author":"JC-C Wei","year":"2020","unstructured":"Wei JC-C, Tsou H-K, Leong P-Y, Chen C-Y, Huang J-X (2020) Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial. Front Med 7:566160. https:\/\/doi.org\/10.3389\/fmed.2020.566160","journal-title":"Front Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07194-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07194-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07194-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:05:30Z","timestamp":1732187130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07194-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7194"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07194-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in accordance with the ethical standards laid down in the Helsinki Declaration of 1975 and its later amendments in 2000, and approved by The Medical Research Ethics Committee, Faculty of Medicine\u2014Sohag University under IRB registration number: Soh-Med-22\u201309-06. All patients included in this study gave written informed consent to participate in this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"It is a single-center, small sample-size study, limited by biological and targeted therapy costs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study Limitations"}}]}}